New Hepatitis C Treatment Therapies at the CLDT

Recently, the development of new drugs for hepatitis C has changed the management of liver transplant patients. Two newly approved medications are now being combined with traditional treatments to form a powerful new drug cocktail, improving the outcomes among patients with this challenging disease. The new cocktail, part of the arsenal of treatment at the Center for Liver Disease and Transplantation, adds the newly approved drugs (telaprevir and boceprevir) to antivirals already in use for Hepatitis C (pegylated interferon and ribavirin). Together, the formula increases the cure rate from 40-50% to 70-80% and shortens the treatment time by half.

Join us November 14th at 1:00 PM/ET on Columbia Surgery Blog Talk Radio to chat with Hepatologist Elizabeth Verna, MD, MS, Assistant Professor of Medicine at NYP/Columbia’s Center for Liver Disease and Transplantation and Robert S. Brown Jr., MD, MPH, Director of the Center for Liver Disease and Transplantation. Speak to our experts about these new and exciting treatment options and learn more about Hepatitis C and the triple viral therapy medications. Dr. Verna and Dr. Brown will answer your questions live, such as:

• How does the triple viral therapy medications work together to better target the Hepatitis C infection?
• What is triple viral therapy’s role in liver transplantation?

To submit a question for our doctors before the show, visit our question submission form or tweet an “@” reply to @columbiasurgery.